Potential examples of such tumor-agnostic targets other than NTRK include (but not limited to) ALK, BRAF, BRCAness, FGFR, HER2, HER3, homologous recombination deficiency (HRD), KRAS, RET, ROS1, tumor mutation burden (TMB) high. This evidence concerns the gene ALK and neoplasm.